Quote: "That study is a recapitulation of many academic center findings to show similar results can be had in the outpatient setting. Its findings have nothing to do with assessing drug effects on these parameters. I think we are discussing very different things...there is a difference between observing the well-known AD effects on P300 (on both amplitude and latency) and being able to use them to measure drug effects."
Think of it this way. They want to find out if A2-73 fundamentally has an impact on cellular homeostasis and brain health. You look at tests that distinguish between people with Alzheimer's disease and those who don't have it. Then you use this test to determine how well the drug does in making Alzheimer's patients closer to normal.
In all of the more modern studies I can find that use automated methods of conducting and interpreting ERP P300 type results, they find that for Alzheimer's patients, three things happen. The P300 amplitude declines, latency increases and reaction time increases.
Table 1 on page "2391" show NC (normal controls), MCI (Mild Cognitive Impairment), AD (Alzheimer's disease) compared together.
From this study, it can be seen that both amplitude and reaction time are better than latency for distinguishing between AD and non-AD. Reaction time is a very good test based on that and other more modern studies.
Market Data 
Markets 
AI
